EL
stock Consumer Defensive Household & Personal ProductsOverall Concerning · 17%
- Fundamentals Weak
- Trajectory Slipping
- Leadership Churning
A read across fundamentals, recent price & growth trajectory, and leadership stability. For fun and reading at a glance, not investment advice.
What the indicators say
Bearish 0 of 5 trend signals bullishRSI 45 — soft momentum, not yet oversold.
A mechanical reading of the chart’s indicators — not investment advice.
Key statsas of Jul 13
- Open
- $82.49
- -0.21%
- Close
- $81.15
- -1.83%
- Current
- $81.15
- Prev close
- $82.66
- Today
- 1.79M
- 3-mo avg
- 3.65M
Earningscalendar synced from Yahoo 57d ago
- Most recent
- May 181 days ago
- Next expected
- Jul 25in 4 days · estimated from cadence
Recent earnings dates
- May 1 81 days ago
- Feb 5 166 days ago
- Oct 30, 2025 264 days ago
- Aug 20, 2025 335 days ago
Past earnings dates come from EL’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.
Fundamentalssynced from SEC 51d ago
Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), EL’s fundamentals read as weak overall.
Earnings per share were negative, so a P/E cannot be formed; the company was unprofitable over the period.
Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.
A 2.1% yield is a healthy, generally sustainable level of cash income.
The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.
A -7.9% margin is thin; little of each revenue dollar survives as profit.
The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.
A -29.3% return on equity is weak; owners' capital is barely being put to work.
Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.
A -5.7% return on assets is low; the asset base is generating little profit.
Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.
Not enough data to compute debt-to-equity.
Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.
At 1.30, short-term assets cover short-term bills with a little room to spare.
Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.
Revenue fell 8.2% from the prior year; the top line is contracting.
Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.
Profit swung to a loss from a profitable prior year.
Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.
Financialssynced from SEC 51d ago
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $16.2B | $17.7B | $15.9B | $15.6B | $14.3B |
| Net income | $2.9B | $2.4B | $1.0B | $409.0M | -$1.1B |
| Diluted EPS | $7.79 | $6.55 | $2.79 | $1.08 | $-3.15 |
| Dividend / share | $2.07 | $2.33 | $2.58 | $2.64 | $1.71 |
| Total assets | $22.0B | $20.9B | $23.4B | $21.7B | $19.9B |
| Total liabilities | — | — | — | — | — |
| Shareholder equity | $6.1B | $5.6B | $5.6B | $5.3B | $3.9B |
| Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 | Q3-2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.9B | $3.4B | $4.0B | $3.5B | $3.4B | $3.5B | $4.2B | $3.7B |
| Net income | -$286.0M | -$156.0M | -$590.0M | $159.0M | -$546.0M | $47.0M | $162.0M | $89.0M |
| Diluted EPS | $-0.79 | $-0.43 | $-1.64 | $0.44 | $-1.52 | $0.13 | $0.44 | $0.24 |
| Dividend / share | $0.66 | $0.66 | $0.35 | $0.35 | $0.35 | $0.35 | $0.35 | $0.35 |
Leadershipsynced from SEC 57d ago
- Lauder Ronald S Chairman, Clinique Labs, LLC
- Fribourg Paul J Director
- Lauder William P Director
- Long Annabelle Yu Director
- Sternlicht Barry S Director
- Zinterhofer Eric Louis Director
Officers and board are drawn from EL’s recent SEC ownership filings (Forms 3, 4 and 5).
Notable recent eventspast year
- May 22 +11.9% one-day move
- Mar 24 −9.8% one-day move
- Mar 23 New 6-month low (-34% off peak)
- Mar 23 −7.7% one-day move
- Mar 12 −7.9% one-day move
- Mar 2 −8.5% one-day move
- Feb 5 −19.2% one-day move
- Dec 2, 2025 +5.2% one-day move
- Oct 13, 2025 +5.8% one-day move
- Oct 10, 2025 −6.7% one-day move
- Aug 21, 2025 Officer or director change reported in an 8-K
Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.
Dividendssynced from Yahoo 52d ago
- 2025 total
- $1.40
- 2026 so far
- $0.702 payments
- 2026 projected
- $1.40+0.0% vs 2025
Projection scales EL’s declared payments so far this year up to the inferred cadence, then compares to last year’s total. Between payouts it is an estimate, not a guarantee.
Payment history
- May 29 $0.35
- Feb 27 $0.35
- Nov 28, 2025 $0.35
- Sep 2, 2025 $0.35
- May 30, 2025 $0.35
- Feb 28, 2025 $0.35
- Nov 29, 2024 $0.35
- Aug 30, 2024 $0.66
- May 31, 2024 $0.66
- Feb 28, 2024 $0.66
- Nov 29, 2023 $0.66
- Aug 30, 2023 $0.66
- May 30, 2023 $0.66
- Feb 27, 2023 $0.66
- Nov 29, 2022 $0.66
- Aug 30, 2022 $0.60
- May 27, 2022 $0.60
- Feb 25, 2022 $0.60
- Nov 29, 2021 $0.60
- Aug 30, 2021 $0.53
Recent SEC filingssynced from SEC 51d ago
- 8-K/A Current report (amended)
- 10-Q Quarterly report
- 8-K Current report
- 8-K/A Current report (amended)
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K/A Current report (amended)
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- DEF 14A Proxy statement
- 8-K Current report
- 10-K Annual report
- 8-K Current report
- 8-K/A Current report (amended)